Palejwala N V, Lauer A K
Retina Vitreous Division, Casey Eye Institute, Department of Ophthalmology, Oregon Health and Science University, Portland, Oregon, USA.
Drugs Today (Barc). 2014 Dec;50(12):779-90. doi: 10.1358/dot.2014.50.12.2245587.
In the last decade, intravitreal medications targeted to vascular endothelial growth factor (VEGF) such as pegaptanib, ranibizumab and bevacizumab have revolutionized the treatment and significantly improved visual acuity outcomes in patients with retinal vascular diseases such as age-related macular degeneration (AMD), diabetic macula edema (DME) and retinal vein occlusion (RVO). In recent years, aflibercept, an anti-VEGF drug that targets all isoforms of VEGF as well as placenta growth factor, has shown similar effectiveness in recent clinical trials. Aflibercept has firmly joined ranibizumab and bevacizu-mab as an important therapeutic option in the management of neovascular AMD. More recently, aflibercept appears to be contending with ranibizumab and bevacizumab as an important therapeutic option in the management of DME and RVO.
在过去十年中，针对血管内皮生长因子（VEGF）的玻璃体内注射药物，如哌加他尼、雷珠单抗和贝伐单抗，彻底改变了视网膜血管疾病（如年龄相关性黄斑变性（AMD）、糖尿病性黄斑水肿（DME）和视网膜静脉阻塞（RVO））的治疗方式，并显著改善了患者的视力预后。近年来，阿柏西普，一种靶向VEGF所有亚型以及胎盘生长因子的抗VEGF药物，在近期临床试验中显示出相似的疗效。阿柏西普已与雷珠单抗和贝伐单抗一道，成为新生血管性AMD治疗中的重要治疗选择。最近，在DME和RVO的治疗中，阿柏西普似乎也在与雷珠单抗和贝伐单抗竞争成为重要的治疗选择。
